190 related articles for article (PubMed ID: 2537614)
1. Posttransfusion cytomegalovirus infections.
Tegtmeier GE
Arch Pathol Lab Med; 1989 Mar; 113(3):236-45. PubMed ID: 2537614
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus infection.
Climent C; Vélez R; Capriles JA
Bol Asoc Med P R; 1992 Jan; 84(1):31-3. PubMed ID: 1323967
[TBL] [Abstract][Full Text] [Related]
3. Transfusion-transmitted cytomegalovirus infection.
Bowden RA
Hematol Oncol Clin North Am; 1995 Feb; 9(1):155-66. PubMed ID: 7737939
[TBL] [Abstract][Full Text] [Related]
4. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
[TBL] [Abstract][Full Text] [Related]
5. Neonatal cytomegalovirus infections due to blood.
Adler SP
Crit Rev Clin Lab Sci; 1986; 23(1):1-14. PubMed ID: 3004810
[TBL] [Abstract][Full Text] [Related]
6. Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative.
Smith D; Lu Q; Yuan S; Goldfinger D; Fernando LP; Ziman A
Vox Sang; 2010 Jan; 98(1):29-36. PubMed ID: 19695013
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
Winston DJ; Ho WG; Bartoni K; Champlin RE
Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
[TBL] [Abstract][Full Text] [Related]
8. CMV and blood transfusions.
Roback JD
Rev Med Virol; 2002; 12(4):211-9. PubMed ID: 12125013
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation.
Verdonck LF; de Graan-Hentzen YC; Dekker AW; Mudde GC; de Gast GC
Bone Marrow Transplant; 1987 Jun; 2(1):73-8. PubMed ID: 2844337
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus infection in seronegative patients treated with prophylaxis: case-controlled study.
Moreno de la Higuera Díaz MA; Calvo Romero N; Sánchez-Fructuoso A; Conesa J; Marques Vidas M; Prats D; Barrientos Guzmán A
Transplant Proc; 2007 Sep; 39(7):2231-2. PubMed ID: 17889147
[TBL] [Abstract][Full Text] [Related]
12. Congenital cytomegalovirus infection as a preventable complication of maternal transfusion. A case report.
McGregor JA; Rubright G; Ogle JW
J Reprod Med; 1990 Jan; 35(1):61-4. PubMed ID: 2153814
[TBL] [Abstract][Full Text] [Related]
13. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.
Roback JD; Conlan M; Drew WL; Ljungman P; Nichols WG; Preiksaitis JK
Transfus Med Rev; 2006 Jan; 20(1):45-56. PubMed ID: 16373187
[TBL] [Abstract][Full Text] [Related]
14. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction.
Wu Y; Zou S; Cable R; Dorsey K; Tang Y; Hapip CA; Melmed R; Trouern-Trend J; Wang JH; Champion M; Fang C; Dodd R
Transfusion; 2010 Apr; 50(4):776-86. PubMed ID: 19912585
[TBL] [Abstract][Full Text] [Related]
15. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
Narvios AB; Lichtiger B
Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
[TBL] [Abstract][Full Text] [Related]
16. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients.
Varga M; Rajczy K; Telkes G; Hídvégi M; Péter A; Remport A; Korbonits M; Fazakas J; Toronyi E; Sárváry E; Kóbori L; Járay J
Nephrol Dial Transplant; 2008 Aug; 23(8):2673-8. PubMed ID: 18332066
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus infection in a neonatal intensive care unit. Subsequent morbidity and mortality of seropositive infants.
Griffin MP; O'Shea M; Brazy JE; Klein D; Koepke J; Malloy C; Wilfert CM
J Perinatol; 1990 Mar; 10(1):43-5. PubMed ID: 2156031
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis and treatment of infection in the bone marrow transplant recipient.
Winston DJ
Curr Clin Top Infect Dis; 1993; 13():293-321. PubMed ID: 8397916
[TBL] [Abstract][Full Text] [Related]
19. Transfusion-transmitted cytomegalovirus infections: significance and control.
Tegtmeier GE
Vox Sang; 1986; 51 Suppl 1():22-30. PubMed ID: 3017003
[TBL] [Abstract][Full Text] [Related]
20. Use of deglycerolized red blood cells to prevent posttransfusion infection with cytomegalovirus in neonates.
Brady MT; Milam JD; Anderson DC; Hawkins EP; Speer ME; Seavy D; Bijou H; Yow MD
J Infect Dis; 1984 Sep; 150(3):334-9. PubMed ID: 6090541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
